European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

IMAGING AND ADVANCED GUIDANCE FOR WORKFLOW OPTIMIZATION IN INTERVENTIONAL ONCOLOGY

Descrizione del progetto

DE EN ES FR IT PL

Progredire nella cura del cancro con tecniche minimamente invasive

L’oncologia interventistica si concentra su procedure minimamente invasive e guidate da immagini per la diagnosi, il trattamento e le cure palliative dei pazienti oncologici. Si tratta di un campo emergente che comprende metodi di ablazione del tumore, biopsie guidate da immagini e interventi per la gestione del dolore o la somministrazione mirata di farmaci. Finanziato dal programma ORIZZONTE, il progetto IMAGIO intende sviluppare percorsi di cura multimodali per tumori maligni aggressivi come il cancro al fegato e ai polmoni, sfruttando tecniche di imaging e terapia interventistica. Il progetto prevede collaborazioni con centri di ricerca, industrie e organizzazioni di pazienti per accelerare l’implementazione di queste tecnologie minimamente invasive e trasformare l’assistenza sanitaria, riducendo le complicazioni del trattamento e la degenza dei pazienti.

Obiettivo

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Lung and liver cancers were among the top three leading causes of cancer death in 2020 with 1.8 million and 830.000 deaths, respectively. On the other hand, soft tissue sarcomas are relatively uncommon cancers diagnosed in about 1% of all adults, but much more common in children and young adults, accounting for 7–10% of paediatric malignancies; they are an important cause of death in the 14–29 years age group.

Interventional Oncology involves miniaturized instruments (biopsy needles, ablation electrodes, intravascular catheters) and minimally-invasive access, guided by imaging techniques (X-ray, ultrasound, computed tomography, magnetic resonance imaging) – to target cancer with ablative or localized drug delivery strategies. Interventional Oncology can be used as a stand-alone approach, or in combination with the other approaches (‘pillars’) to enhance treatment efficacy.

While cancer survival has significantly improved over time through innovations in each individual pillar, our current understanding of cancer now leads us to an intertwining of pillars and multimodal care pathways: Interventional Oncology is uniquely suited to leverage and enhance the effects of the conventional therapy pillars, while reducing the burden on the healthcare system.

IMAGIO will leverage Interventional Oncology in the clinical setting to improve the cancer survival outcomes, through minimally invasive, efficient, and affordable care.
We will deliver four complete, multimodal care pathways for two of the most aggressive cancers (liver, lung) and one of the most debilitating when treated with current approaches (sarcoma):
1. Multimodal interventional imaging for fast and precise radioembolization therapy of liver cancer;
2. Multimodal ablation therapy of liver cancer;
3. Multimodal diagnosis and therapy in early-stage lung cancer; and
4. Multimodal MR-HIFU-enabled therapy for abdominal sarcoma.

IMAGIO will mature the next-generation interventional imaging across the full spectrum, from pre-clinical developments to impact validation in clinical trials. Expertise on Interventional Oncology and immunotherapy will be leveraged from pioneering clinical research centres and leading industry covering the full value chain of oncological care, as well as cancer patient and professional organisations. Such synergetic partnerships will accelerate the impact of the technologies and transform the way healthcare solutions are delivered, providing access to safe, fast, and effective care. By focusing on the local delivery of therapy, IMAGIO will drive the substitution of conventional higher dose systemic alternatives or invasive surgical approaches, thereby accelerating recovery, reducing complication rates and the number of patient visits.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

HORIZON-JU-IHI-2022-01-single-stage

Vedi altri progetti per questo bando

Meccanismo di finanziamento

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

Coordinatore

PHILIPS MEDICAL SYSTEMS NEDERLAND BV
Contribution nette de l'UE
€ 5 668 325,00
Indirizzo
VEENPLUIS 6
5684 PC Best
Paesi Bassi

Mostra sulla mappa
Regione
Zuid-Nederland Noord-Brabant Zuidoost-Noord-Brabant
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 11 336 650,00

Partecipanti (29)

Partner (2)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 26 Giugno 2023

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/101112053/it

European Union, 2024